These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19882663)

  • 21. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PML-RAR alpha fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome.
    Ikeda K; Sasaki K; Tasaka T; Nagai M; Kawanishi K; Takahara J; Irino S
    Int J Hematol; 1994 Oct; 60(3):197-205. PubMed ID: 7858239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of minimal residual disease in patients with acute myeloid leukemia].
    Gal'tseva IV; Savchenko VG; Kulikov SM; Parovichnikova EN; Miterev GIu; Maslova ER; Isaev VG
    Ter Arkh; 2003; 75(7):8-14. PubMed ID: 12934474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia.
    Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtiö J
    J Proteome Res; 2008 Jun; 7(6):2332-41. PubMed ID: 18452325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
    Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
    Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
    Gau JP; Young JH; Lin TH; Yang YS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):175-81. PubMed ID: 10746412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.
    Elmaagacli AH; Beelen DW; Trenschel R; Schaefer UW
    Bone Marrow Transplant; 2000 Jan; 25(1):91-6. PubMed ID: 10654021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
    Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
    Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
    Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
    Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia.
    Diverio D; Riccioni R; Mandelli F; Lo Coco F
    Haematologica; 1995; 80(2):155-60. PubMed ID: 7628753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monitoring of minimal residual disease in patients with acute promyelocytic leukemia].
    Shuravina EN; Parovichnikova EN; Demidova IA; Misiurin AV; Isaev VG; Ol'shanskaia IuV; Savchenko VG
    Ter Arkh; 2006; 78(7):25-31. PubMed ID: 16944747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.
    Gameiro P; Vieira S; Carrara P; Silva AL; Diamond J; Botelho de Sousa A; Mehta AB; Prentice HG; Guimarães JE; Hoffbrand AV; Foroni L; Parreira A
    Haematologica; 2001 Jun; 86(6):577-85. PubMed ID: 11418366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Identification and investigation of disease-related peptides in sera from patients with chronic hepatitis B].
    Li M; Wang J; Dai E; Liu D
    Wei Sheng Yan Jiu; 2011 May; 40(3):315-9. PubMed ID: 21695902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical significance of hemostatic molecular markers in acute leukemia].
    Wu F; Wang X; Qu B; Huang X; Wang H
    Zhonghua Xue Ye Xue Za Zhi; 2001 Mar; 22(3):141-4. PubMed ID: 11877066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression and significance of stathmin1 in acute leukemia].
    Xu JP; Hu JD; Li J; Liu TB; Lin MH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1105-10. PubMed ID: 24156415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia.
    Song W; Wang N; Li W; Wang G; Hu J; He K; Li Y; Meng Y; Chen N; Wang S; Hu L; Xu B; Wang J; Li A; Cui J
    Oncol Lett; 2013 Nov; 6(5):1453-1460. PubMed ID: 24179540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.